Epidemiological evidence that common HPV types may be common because of their ability to evade immune surveillance: Results from the Women's Interagency HIV study

· 2019-10-18

Infection by human papillomavirus (HPV) type 16, the most oncogenic HPV type, was found to be the least affected by HIV‐status and CD4 count of any of the approximately 13 oncogenic HPV types. This relative independence from host immune status has been interpreted as evidence that HPV16 may have an innate ability to avoid the effects of immunosurveillance. However, the impact of immune status on other individual HPV types has not been carefully assessed. We studied type‐specific HPV infection in a cohort of 2,470 HIV‐positive (HIV[+]) and 895 HIV‐negative (HIV[−]) women. Semi‐annually collected cervicovaginal lavages were tested for >40 HPV types. HPV type‐specific prevalence ratios (PRs), incidence and clearance hazard ratios (HRs), were calculated by contrasting HPV types detected in HIV[+] women with CD4 < 200 to HIV[−] women. HPV71 and HPV16 prevalence had the weakest associations with HIV‐status/CD4 count of any HPV, according to PRs. No correlations between PRs and HPV phylogeny or oncogenicity were observed. Instead, higher HPV type‐specific prevalence in HIV[−] women correlated with lower PRs (ρ = −0.59; p = 0.0001). An alternative (quadratic model) statistical approach (PHIV+ = a*PHIV− + b*PHIV−2; R2 = 0.894) found similar associations (p = 0.0005). In summary, the most prevalent HPV types in HIV[−] women were the types most independent from host immune status. These results suggest that common HPV types in HIV[−] women may have a greater ability to avoid immune surveillance than other types, which may help explain why they are common.

Funding
Miami Womens Interagency HIV Study WIHSBrooklyn Women's Interagency HIV Study (WIHS) VWomen's Interagency HIV Study (WIHS-V)The Connie Wofsy Women's HIV StudyCenter/Coordination, Analysis and Management/MACSUAB-MISS WIHS CohortMACS/WIHS Combined Cohort Study: Brooklyn Clinical Research Site (Bklyn CRS)HPV & Cervix Neoplasia in a Large, Long Term HIV + CohortEmory WIHS CRS - Longitudinal CohortNext Generation of HPV and Cervical Cancer Research in HIV+ WomenWashington Women's Interagency HIV/AIDS StudyMolecular Methods to Improve Cervical Cancer Screening in HIV+ WomenAtlanta Clinical and Translational Science Institute (ACTSI) RenewalData Analysis and Coordination Center for the MACS-WIHS Combined Cohort StudyUniversity of North Carolina Womens Interagency HIV Study UNC WIHSChicago WIHS Consortium V (CWC)Tumor Microenvironment and Metastasis ProgramClinical and Translational Science InstituteUNC Center for AIDS Research Core A AdministrationSouthern California Women's Interagency HIV Study ConsortiumWIHS Data Management and Analysis Center (WDMAC)National Cancer Institute Grant R01‐CA‐230331National Cancer Institute Grant R01‐CA‐085178National Cancer Institute Grant R01‐CA‐174634

NIAID NIH HHS

U01 AI103397

NIAID NIH HHS

U01 AI031834

NIAID NIH HHS

U01 AI035004

NIAID NIH HHS

U01 AI034989

NIAID NIH HHS

UM1 AI035043

NIAID NIH HHS

U01 AI103401

NHLBI NIH HHS

U01 HL146202

NCI NIH HHS

R01 CA085178

NIAID NIH HHS

U01 AI103408

NCI NIH HHS

R01 CA230331

NIAID NIH HHS

U01 AI034994

NCI NIH HHS

R01 CA174634

NCATS NIH HHS

UL1 TR000454

NHLBI NIH HHS

U01 HL146193

NIAID NIH HHS

U01 AI103390

NIAID NIH HHS

U01 AI034993

NCI NIH HHS

P30 CA013330

NCATS NIH HHS

UL1 TR000004

NIAID NIH HHS

P30 AI050410

NICHD NIH HHS

U01 HD032632

NIAID NIH HHS

U01 AI042590